In this article we are going to estimate the intrinsic value of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by taking the expected future cash flows and discounting them to their present value.

Analysts expect the Boston, Massachusetts-based company to report quarterly earnings at $4.02 per share, down from $4.20 per share in the year-ago period. Vertex Pharmaceuticals projects quarterly ...

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be reporting results tomorrow afternoon. Here’s what to look for.

Stock indexes today are mildly higher, led by gains in US metals makers and mining stocks after President Trump imposed a 25% tariff on US steel and aluminum imports.  The tariff increases also ...

U.S. stock futures rose on Monday following Friday's sharp fall as investors digest tariff updates and earnings reports.

U.S. stock index futures edged higher on Sunday evening as investors engaged in dip-buying after steep losses on Friday. The ...

As the quarterly earnings season continues, the upcoming week promises a flurry of reports from some of the most influential companies spanning various industries. In the consumer sector, Coca-Cola ...

To illustrate that point, let's discuss two stocks in the biotech industry that have moved in opposite directions so far this ...

We recently compiled a list of the 13 Best Natural Gas and Oil Dividend Stocks To Buy. In this article, we are going to take ...

Truist Financial analyst Joon Lee maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report) today. The company’s shares closed ...

CDC data shows that people are seeking medical care for flu-like symptoms at the highest rates since 2009 during the swine ...

In a report released today, Alex Thompson CFA from Stifel Nicolaus maintained a Buy rating on Oruka Therapeutics (ORKA – Research Report), with ...